Pyrimethamine_SDS_MedChemExpress
雷帕霉素-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jan.-07-2019Print Date:Jan.-07-20191. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :RapamycinCatalog No. :HY-10219CAS No. :53123-88-91.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Flammable liquids (Category 4), H2272.2 GHS Label elements, including precautionary statementsPictogram No data availableSignal word WarningHazard statement(s)H227 Combustible liquid.Precautionary statement(s)P210 Keep away from heat ⁄sparks ⁄open flames ⁄hot surfaces. - No smoking.P280 Wear protective gloves ⁄ protective clothing ⁄ eye protection ⁄ face protection.P370 + P378 In case of fire: Use dry sand, dry chemical or alcohol-resistant foam for extinction.P403 + P235 Store in a well-ventilated place. Keep cool.P501 Dispose of contents ⁄ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:SirolimusFormula:C51H79NO13Molecular Weight:914.17CAS No. :53123-88-94. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 years* The compound is unstable in solutions, freshly prepared is recommended.Shipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2019 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
高效液相色谱法检测盐酸度洛西汀肠溶胶囊中α-萘酚杂质
高效液相色谱法检测盐酸度洛西汀肠溶胶囊中α-萘酚杂质隋海山;戚威;王立娟【摘要】目的建立测定盐酸度洛西汀肠溶胶囊中α-萘酚杂质含量的高效液相色谱(HPLC)法.方法采用岛津-GL Inertsil CN-3液相色谱柱(250 mm×4.6 mm,5μm),流动相为乙腈-正丁醇-磷酸缓冲液(13∶17∶70),流速为1.0 mL/min,检测波长230 nm,柱温为40℃.结果α-萘酚含量在8 × 10-4~8×10-3μg范围内与峰面积呈良好线性关系(r=0.997 6),平均回收率为99.08%,RSD为0.89%(n=12).结论该方法专属性强、耐用性好、准确度高,可以控制盐酸度洛西汀肠溶胶囊中α-萘酚的含量.【期刊名称】《中国药业》【年(卷),期】2015(024)024【总页数】3页(P156-158)【关键词】高效液相色谱法;盐酸度洛西汀;α-萘酚;含量测定【作者】隋海山;戚威;王立娟【作者单位】山东省潍坊市食品药品检验检测中心,山东潍坊261041;山东省潍坊市食品药品检验检测中心,山东潍坊261041;山东省潍坊市红十字中心血站,山东潍坊261041【正文语种】中文【中图分类】R927.2;R971+.43高效液相色谱(HPLC)法是目前药物分析中常用的色谱分离、分析技术,具有较高的分析速度及分离效率,且具有检测灵敏度较高、适用测定范围广、样品处理操作简单、回收率高等特点。
随着现代质谱、核磁共振波谱等色谱技术的日益成熟及色谱联用技术的发展,HPLC法在药物制剂分析中的应用越来越广泛[1-2]。
因此,笔者通过建立HPLC法对盐酸度洛西汀肠溶胶囊中所含有的特殊杂质α-萘酚进行分离分析,控制药物中杂质α-萘酚的含量,以减少药物中所含杂质对人体造成的损害。
Aglient 1260型高效液相色谱仪(安捷伦<中国>科技有限公司);DZF-150型恒温真空干燥箱(郑州长城科工贸有限公司);KQ5200DE型数控超声波清洗器(昆山市超声仪器有限公司);PT25S型电子分析天平(赛多利斯科学仪器有限公司);ZF-20C型暗箱式紫外分析仪(上海和勤科学分析仪器有限公司);BSZ-160F型电脑自动部分收集器(上海精科实业有限公司)。
高密度脂蛋白胆固醇测定试剂盒(直接法-过氧化氢酶清除法)产品技术要求baiding
高密度脂蛋白胆固醇测定试剂盒(直接法-过氧化氢酶清除法)适用范围:本试剂用于体外定量测定人血清中高密度脂蛋白胆固醇的含量。
1.1 包装规格产品组成:2.1 外观2.1.1 试剂1为无色透明液体,无混浊,无未溶解物。
2.1.2 试剂2为淡黄褐色透明液体,无混浊,无未溶解物。
2.1.3 校准品为无色或浅黄色冻干粉,溶解后为无色或黄色液体,无未溶解物。
2.1.4 标签内容清晰,字迹牢固不易脱落。
2.2 试剂装量液体试剂的净含量不少于标示值。
2.3 含水量校准品冻干粉含水量≤3%。
2.4 试剂空白吸光度A≤0.080(光径1.0cm,600nm±20nm 波长)。
2.5 分析灵敏度测定1.0mmol/L样本,吸光度变化在0.04~0.08范围内。
2.6 线性区间2.6.1 [0.20,2.50]mmol/L。
在规定的线性范围内,测定值与样本浓度值的相关系数(r)应不低于0.990。
2.6.2 [0.2,0.8] mmol/L范围内,线性绝对偏差应不超过±0.08 mmol /L;(0.8,2.5] mmol /L范围内,线性相对偏差应不超过±10%。
2.7 精密度2.7.1 重复性变异系数CV≤4.0%。
2.7.2 批内瓶间差试剂盒内校准品瓶间差CV≤4%。
2.7.3 批间差批间差≤6.0%。
2.8 准确度相对偏差在±10%范围内(测试国际参考物质SRM 1951b(NIST))。
2.9 稳定性2.9.1 校准品冻干粉复溶后在2℃~8℃避光保存稳定7天,测定结果应符合2.8要求。
2.9.2 原装试剂2℃~8℃保存,有效期12个月,有效期满后2个月内测定结果应符合2.1、2.4、2.5、2.6、2.7.1和2.8要求。
SDS增敏荧光光度法测定人血清中左氧氟沙星的残留量
SDS增敏荧光光度法测定人血清中左氧氟沙星的残留量
董学芝;席会平;胡卫平;李畅;张国胜
【期刊名称】《华西药学杂志》
【年(卷),期】2007(22)4
【摘要】目的建立人血清中左氧氟沙星(LOX)残留量的快速测定方法。
方法采用十二烷基硫酸钠(SDS)增敏荧光光度法。
结果用无水乙醇沉淀蛋白,对血清进行预处理,利用LOX-SDS体系测定,人血清中LOX在0.1~5.0μg.ml-1时,荧光强度与浓度呈线性关系,其回归方程为:F=5.552+40.019C(r=0.9990),平均回收率为
99.72%,RSD=0.68%。
结论所建方法简便、准确、快速,可用于人血清中LOX的测定。
【总页数】3页(P435-437)
【关键词】十二烷基硫酸钠增敏荧光分光光度法;左氧氟沙星;血清;残留量
【作者】董学芝;席会平;胡卫平;李畅;张国胜
【作者单位】河南大学化学化工学院
【正文语种】中文
【中图分类】R917
【相关文献】
1.CTMAB增敏荧光光度法测定牛奶中莫西沙星残留量 [J], 蔡花真;董贺;席会平;龚文琪
2.聚乙二醇辛基苯基醚胶束增敏荧光分光光度法测定人尿中痕量1-羟基芘 [J], 欧
阳运富;王永生;唐宏兵
3.微乳液增敏对硝基苯基荧光酮光度法测定人发中痕量镍 [J], 杜斌;吴丹;魏琴;张慧;欧庆瑜
4.功能性CdS纳米荧光探针荧光增敏法测定人血清白蛋白 [J], 汪乐余;周运友;朱昌青;张明翠;陶海升;王伦
5.新荧光试剂5-(4-羧基苯偶氮)-8-水杨醛缩氨基喹啉荧光增敏法测定人血清蛋白质 [J], 张明翠;汪乐余;李玲;陈红旗;张德兴;王伦
因版权原因,仅展示原文概要,查看原文内容请购买。
植物类黄酮-3’,5’-羟化酶(F3 ’ ,5 ’H )试剂盒(ELISA)使用说明书
植物类黄酮-3’,5’-羟化酶(F3 ’ ,5 ’H )试剂盒(ELISA)使用说明书⚫本试剂盒用于体外定量检测组织、细胞及相关液体样本中植物类黄酮-3’,5’-羟化酶(F3 ’ ,5 ’H )的含量。
⚫有效期:6个月⚫保存条件:2-8℃⚫本试剂盒仅供科研使用,不得用于临床诊断实验原理试剂盒采用双抗体一步夹心法酶联免疫吸附试验(ELISA)。
往预先包被植物类黄酮-3’,5’-羟化酶(F3 ’ ,5 ’H )捕获抗体的包被微孔中,依次加入标本、标准品、HRP标记的检测抗体,经过温育并彻底洗涤。
用底物TMB显色,TMB在过氧化物酶的催化下转化成蓝色,并在酸的作用下转化成最终的黄色。
颜色的深浅和样品中的植物类黄酮-3’,5’-羟化酶(F3 ’ ,5 ’H )呈正相关。
用酶标仪在450nm 波长下测定吸光度(OD 值),计算样品浓度。
样本处理及要求1. 血清:将收集于血清分离管的全血标本在室温放置2小时或4℃过夜,然后1000×g离心20分钟,取上清即可,或将上清置于-20℃或-80℃保存,但应避免反复冻融。
2. 血浆:用EDTA或肝素作为抗凝剂采集标本,并将标本在采集后的30分钟内于2-8℃1000×g离心15分钟,取上清即可检测,或将上清置于-20℃或-80℃保存,但应避免反复冻融。
3. 组织匀浆:用预冷的PBS (0.01M, pH=7.4)冲洗组织,去除残留血液(匀浆中裂解的红细胞会影响测量结果),称重后将组织剪碎。
将剪碎的组织与对应体积的PBS(一般按1:9的重量体积比,比如1g的组织样品对应9mL的PBS,具体体积可根据实验需要适当调整,并做好记录。
推荐在PBS中加入蛋白酶抑制剂)加入玻璃匀浆器中,于冰上充分研磨。
为了进一步裂解组织细胞,可以对匀浆液进行超声破碎,或反复冻融。
最后将匀浆液于5000×g离心5~10分钟,取上清检测。
4. 细胞培养物上清或其它生物标本:请1000×g离心20分钟,取上清即可检测,或将上清置于-20℃或-80℃保存,但应避免反复冻融。
低密度脂蛋白胆固醇测定试剂盒(直接法—表面活性剂清除法)产品技术要求广州伊川生物
低密度脂蛋白胆固醇测定试剂盒(直接法-表面活性剂清除
法)性能指标
1外观和性状
1.1试剂盒各组分应齐全、完整、无液体渗漏;中文包装标签应清晰,准确、牢固;
1.2试剂 R1 应为无色澄清液体、无沉淀、无悬浮物、无絮状物。
1.3试剂 R2 应为无色或淡黄色澄清液体,无沉淀、无悬浮物、无絮状物。
2
净含量
液体试剂的装量应不小于标示量。
3 准确度
使用有证参考物质或其他公认的参考物质进行测定,实测值与标示值的相对偏差应不超过±10%。
4 分析灵敏度
LDL-C 含量为 1.00mmol/L 时,平均吸光度差值(△A)>0.03。
5 试剂空白吸光度
在温度37℃、波长 546nm 条件下检测,试剂空白吸光度值应<0.05(比色杯光径1.0cm)。
6线性区间
6.1线性区间为 0.30mmol/L ~12.90mmol/L,在 0.30mmol/L ~12.90mmol/L 区间内,理论浓度与实测浓度的线性相关系数 r 应≥0.995。
6.2[0.30,12.90]mmol/L 区间内,线性偏差应不超过±0.30mol/L或不超过± 10%。
(温度37℃、波长 5460nm、比色杯光径 1.0cm)
7精密度
7.1重复性:
重复测试(2.50±0.50)mmol/L 和(5.00±1.00)mmol/L 的样本,所得结果的
变异系数(CV)应不大于 3%。
7.2批间差
测试(2.50±0.50)mmol/L 的样本,所得结果的批间相对极差(R)应不大于 10%。
1,5-脱水-D-山梨醇测定试剂盒(吡喃糖氧化酶法)产品技术要求乐普(北京)诊断技术
1,5-脱水-D-山梨醇测定试剂盒(吡喃糖氧化酶法)适用范围:用于体外定量测定人血清或血浆中1,5-脱水-D-山梨醇(1,5-AG)的含量。
.包装规格试剂1:3×60 mL,试剂2:3×20 mL;试剂1:1×60 mL,试剂2:1×20 mL;试剂1:2×45 mL,试剂2:2×15 mL;试剂1:1×45 mL,试剂2:1×15 mL;试剂1:1×30 mL,试剂2:1×10 mL;试剂1:1×21 mL,试剂2:1×7 mL;试剂1:1×18 mL,试剂2:1×6 mL;试剂1:24×3.8 mL,试剂2:12×2.6 mL;校准品:1×2 mL(选配);质控品:2×2 mL(两水平)(选配)。
2.1 外观试剂1:无色澄清液体;试剂2:黄色澄清液体。
校准品:无色至淡黄色透明液体。
质控品:无色至淡黄色透明液体。
外包装完好、无破损,标签完好、字迹清晰。
2.2 装量液体试剂的装量应不少于标示值。
2.3 试剂空白吸光度在546nm处测定试剂空白吸光度应≤0.1000。
2.4 分析灵敏度样本浓度为150μmol/L时,其吸光度变化在0.0250-0.1500范围内。
2.5 准确度参照CLSI EP9-A2的方法,与比对试剂盒同时测试40例线性范围内的不同浓度的血清样本,在[6.0,300.0]μmol/L区间内相关系数r应不小于0.975。
[6.0,30.0]μmol/L区间内绝对偏差应不超过±3.0μmol/L,(30.0,300.0]μmol/L 区间内相对偏差应不超过±10%。
2.6 线性在[6.0,300.0]μmol/L区间内线性相关系数r应不小于0.990。
[6.0,30.0]μmol/L区间内绝对偏差应不超过±3.0μmol/L,(30.0,300.0]μmol/L区间内相对偏差不超过±10%。
气相色谱法测定非布司他原料药中的基因毒性杂质盐酸羟胺
气相色谱法测定非布司他原料药中的基因毒性杂质盐酸羟胺李彬;李丽婉
【期刊名称】《天津药学》
【年(卷),期】2024(36)2
【摘要】目的:建立了气相色谱衍生化法测定非布司他中潜在基因毒性杂质盐酸羟胺的含量。
方法:用环己酮将盐酸羟胺衍生为环己酮肟,通过气相色谱进行测定。
色谱柱为安捷伦DB-624色谱柱(30 m×0.53 mm,3μm);检测器为氢火焰离子化检测器(FID),检测器的温度260℃;进样口温度为230℃;高纯氮气为载气,恒流模式,流速为1.5 ml/min;色谱柱的升温程序为:起始温度55℃,维持2 min,以20℃/min的升温速率升温至95℃,维持2 min,再以40℃/min的升温速率升温至250℃,维持20 min。
进样量为1μl;分流比为5:1。
结果:盐酸羟胺在0.2247~2.696μg/ml范围内,浓度与峰面积线性关系良好(r=0.9997);平均回收率为99.24%~106.59%之间,RSD 为2.29%。
结论:本方法简单,准确度高,重现性好,可用于非布司他原料药中盐酸羟胺的质量控制。
【总页数】4页(P18-21)
【作者】李彬;李丽婉
【作者单位】开封市中医院;上海药明康德新药开发有限公司
【正文语种】中文
【中图分类】R927.1
【相关文献】
1.气相色谱法测定沙格列汀原料药中基因毒性杂质残留量
2.盐酸兰地洛尔原料药中基因毒性杂质的定量分析方法研究
3.气相色谱法测定盐酸苯海索中潜在基因毒性杂质
4.高效液相法测定5-氟-1H-吲哚-2,3-二酮中基因毒性杂质盐酸羟胺的含量
5.盐酸倍他司汀中基因毒性杂质甲醛的测定
因版权原因,仅展示原文概要,查看原文内容请购买。
普鲁兰酶分子量
普鲁兰酶分子量1. 什么是普鲁兰酶?普鲁兰酶(Prulanease)是一种具有蛋白水解活性的酶。
它属于蛋白酶家族,主要用于在食品工业中进行蛋白质的水解。
2. 普鲁兰酶的分子量普鲁兰酶的分子量是指其分子中所含有的原子总质量。
分子量通常以Dalton(Da)为单位表示。
根据实验测定,普鲁兰酶的分子量约为XX Da。
3. 测定普鲁兰酶分子量的方法测定普鲁兰酶分子量的方法有多种,以下介绍其中两种常用方法:3.1 SDS-PAGESDS-PAGE(聚丙烯胺凝胶电泳)是一种常用于蛋白质分析和纯化的方法。
它通过在凝胶中施加电场,将蛋白质按照其大小进行分离。
在SDS-PAGE中,样品经过还原处理后与SDS(十二烷基硫酸钠)混合,在电泳过程中,蛋白质被SDS包裹,使其带有负电荷,从而消除了蛋白质本身的电荷影响,只与其大小有关。
通过与已知分子量的标准品进行比较,可以确定普鲁兰酶的分子量。
3.2 质谱法质谱法是一种直接测定蛋白质分子量的方法。
它利用质谱仪对蛋白质进行离子化和分析,根据离子在磁场中的偏转程度或飞行时间来计算其分子量。
质谱法具有高灵敏度、高准确性和高分辨率等优点,可以精确地测定普鲁兰酶的分子量。
4. 普鲁兰酶分子量与其功能的关系普鲁兰酶的分子量与其功能密切相关。
普鲁兰酶通过水解蛋白质中的肽键将大分子蛋白质降解为小分子肽段或氨基酸。
其作用是促进食品中蛋白质的降解和消化吸收,提高食品口感和营养价值。
普鲁兰酶的分子量越大,其对蛋白质的水解能力可能越强,因此在食品工业中选择合适分子量的普鲁兰酶可以达到更好的效果。
5. 普鲁兰酶在食品工业中的应用普鲁兰酶在食品工业中具有广泛的应用。
以下是一些常见的应用领域:5.1 面包和面团制作在面包和面团制作过程中,普鲁兰酶可以通过水解蛋白质中的胺基酸残基来改善面团的性质。
它可以增加面团的延展性和可塑性,改善面包的口感和质地。
5.2 肉制品加工普鲁兰酶在肉制品加工中起到催化作用。
帕瑞昔布钠遗传毒性杂质及其制备方法[发明专利]
专利名称:帕瑞昔布钠遗传毒性杂质及其制备方法专利类型:发明专利
发明人:齐创宇,罗国军,严宏营,钟慧,张艳,杜狄峥申请号:CN201911179971.6
申请日:20191127
公开号:CN110938043A
公开日:
20200331
专利内容由知识产权出版社提供
摘要:本发明涉及一种帕瑞昔布钠遗传毒性杂质及其制备方法。
制备方法包括:于温度‑5℃~0℃下,混合5‑甲基‑3,4‑二苯基异恶唑和二氯甲烷,再<3mL/分钟的速率加入氯磺酸,采用高效液相色谱法监控反应进程,得反应液;将所述反应液淬灭,萃取,然后加入甲醇钠的甲醇溶液、乙醇钠的乙醇溶液或异丙醇钠的异丙醇溶液,反应2h‑4h,得4‑(5‑甲基‑3‑苯基‑4‑异恶唑基)苯磺酸甲酯、
4‑(5‑甲基‑3‑苯基‑4‑异恶唑基)苯磺酸乙酯或4‑(5‑甲基‑3‑苯基‑4‑异恶唑基)苯磺酸异丙酯。
上述方法制得的3种帕瑞昔布钠遗传毒性杂质纯度可以达到99.5%以上,甚至是99.73%;收率可以达到67%以上,甚至是71.0%。
申请人:上海秀新臣邦医药科技有限公司
地址:200135 上海市浦东新区中国(上海)自由贸易试验区祖冲之路1505弄80号13幢四楼B区国籍:CN
代理机构:广州华进联合专利商标代理有限公司
代理人:杜寒宇
更多信息请下载全文后查看。
一种小而密低密度脂蛋白胆固醇检测试剂盒[发明专利]
专利名称:一种小而密低密度脂蛋白胆固醇检测试剂盒专利类型:发明专利
发明人:郑丽丽
申请号:CN201810233833.0
申请日:20180321
公开号:CN108424952A
公开日:
20180821
专利内容由知识产权出版社提供
摘要:本发明提供了一种小而密低密度脂蛋白胆固醇检测试剂盒,所述试剂盒为液体双试剂,由试剂R1和试剂R2组成;所述试剂R2由以下组分组成:浓度为0.1‑1.0mol/L的缓冲液,浓度为
100‑200U/L的过氧化物酶,浓度为1.0‑2.5mol/L的4‑氨基安替比林,浓度为40‑60.0mmol/L的曲拉通,浓度为2.5‑5ml/L的稳定剂。
本发明所述的一种小而密低密度脂蛋白胆固醇检测试剂盒,试剂R1和试剂R2中均含有稳定剂,可以显著延长小而密低密度脂蛋白胆固醇检测试剂的开瓶稳定性和效期稳定性,且试剂的准确度高,灵敏高,批间精密度好,能满足临床检验需要。
申请人:天津中成佳益生物科技有限公司
地址:300300 天津市东丽区华明高新技术产业区华丰路6号B座4号楼4层
国籍:CN
更多信息请下载全文后查看。
高效毛细管电泳法测定有毒生物碱
高效毛细管电泳法测定有毒生物碱复旦大学药学院仲艳生物碱(alkaloids)是植物中一类重要的化学成分,大多具有生理活性,往往是许多药用植物的主要有效成分。
对于含有一些毒性较大的生物碱类的中草药,由于剂量不当或者炮制方法有误而导致中毒的情况时有发生。
目前国内外的文献报道主要集中于一种植物来源有毒生物碱的研究上,对于一次操作筛选包含几种植物来源的有毒生物碱的分析方法未见有报道。
高效毛细管电泳(HPCE)[1-3]是近年来迅速发展起来的新的分析技术,与目前常用的气相色谱法(GC),气质联用法(GC-MS)和高效液相色谱法(HPLC)等方法相比,具有高效、快速、低成本、易操作、样品量少等特点,近年来在医学、药学、生化等领域得到了较快的发展和广泛的应用。
在20世纪90年代,CE技术被引入司法领域,用来分离了包括海洛因在内的18种违禁和管制药品。
随着这一技术的推广应用,CE已成为毒物检测中的热点。
本研究以此为切入点,用毛细管区带电泳-紫外检测(CZE-UV)系统分析了检材中常见的几种有毒生物碱。
这一通用性的方法,大大提高未知毒物的分析速度,可作为有毒生物碱初筛的方法。
1 实验部分1.1仪器与药品Beckman P/ACE MDQ毛细管电泳仪(美国Beckman公司);未涂层石英毛细管柱(75μm×50.2cm,有效分离长度为40cm,Beckman公司);Oasis HLB柱(1mL/30mg,Waters公司);旋涡混合器 XW-80A;电热恒温水浴锅。
样品:乌头碱(Aconitine)、次乌头碱(Hypaconitine)、新乌头碱(Mesaconitine)、高乌甲素(Lappaconitine)、雪上一枝蒿甲素(Bullatine A)、硫酸阿托品(Atropine Sulfate)、溴甲阿托品(Atropine Methobromide)、氢溴酸东莨菪碱(Scopolamine Hydrobromide)、氢溴酸山莨菪碱(Anisodamine Hydrobromide)、茶碱(Theophylline)、马钱子碱(Brucine)、士的宁(Strychnine)、硫酸奎宁(Quinine Sulfate)、氯喹(Chloroquine)。
氯替泼诺中残留溶剂甲醇和乙醇的测定
氯替泼诺中残留溶剂甲醇和乙醇的测定
孙红英;刘宪华
【期刊名称】《药学研究》
【年(卷),期】2005(024)011
【摘要】目的建立氯替泼诺中残留甲醇和乙醇的测定方法.方法应用气相色谱仪,氢火焰离子化检测器,检测器温度为250℃,进样口温度210℃,柱温120℃.结果样品中检出乙醇,未检出甲醇.甲醇的线性范围为0.155~0.464mg·ml-1,r=0.9999,回收率为97.4%,RSD=1.85%(n=6).乙醇的线性范围为0.254~0.762mg·ml 1,r=0.9999,回收率为100.5%,RSD=1.21%(n=6).结论该方法简单、准确.
【总页数】2页(P673-674)
【作者】孙红英;刘宪华
【作者单位】山东省医药工业研究所,济南,250100;山东省医药工业研究所,济南,250100
【正文语种】中文
【中图分类】R917
【相关文献】
1.顶空进样GC-SIM-MS测定硝唑尼特中溶剂残留甲醇含量 [J], 吴清盛;茅小燕;孙丽东
2.喜树碱在二甲亚砜和甲醇(或乙醇)混合溶剂中溶解度的测定和关联 [J], 支娟娟;徐家阔;刘琼;李涛;任保增
3.对乙酰氨基苯甲酸在甲醇+乙醇混合溶剂中溶解度测定及关联计算 [J], 田原铭;
李金焕;樊媛洁;张羽昕;沈洋;李群生
4.顶空[4]气相色谱法测定头孢噻肟钠中的残留溶剂──甲醇、乙醇、丙酮、二氯甲烷、四氢呋喃 [J], 张红梅;乔杰
5.磺胺嘧啶中残留溶剂甲醇、乙醇、DMF气相色谱检测方法的建立和验证 [J], 王玉芹;黄桂原;李晴;张卫东
因版权原因,仅展示原文概要,查看原文内容请购买。
特非那定中苯哌啶酮的薄层色谱扫描测定法
特非那定中苯哌啶酮的薄层色谱扫描测定法
刘淑贤;王淑华;王雷
【期刊名称】《中国医药工业杂志》
【年(卷),期】1992(23)3
【摘要】特非那定(苯哌啶醇,terfenadine,1)为组胺 H_1受体拮抗药,化学名为
α(4-叔丁基苯基)-4-(羟基二苯基甲基)-1-哌啶丁醇,用于治疗过敏性鼻炎。
从其合成工艺考虑,有可能带入前步中间体——苯哌啶酮,因此,分离、测定后者在成品中的含量。
【总页数】2页(P125-126)
【关键词】特非那定;薄层色谱;扫描;测定
【作者】刘淑贤;王淑华;王雷
【作者单位】国家医药管理局天津药物研究院
【正文语种】中文
【中图分类】R927.2
【相关文献】
1.发酵液L-亮氨酸的定量测定方法研究 --纸色谱-薄层扫描测定法 [J], 伍时华;李军生;余炜;陈宁;张克旭
2.亲核试剂亲核取代竞争的薄层色谱扫描测定法 [J], 雷皇书;冯地旺
3.薄层色谱扫描法测定四氢叶酸辅酶模型与格氏试剂反应的产物—苯乙酮和二苯甲酮 [J], 周培文;夏炽中;冯育林
因版权原因,仅展示原文概要,查看原文内容请购买。
盐酸氟西汀分散片含量的高效液相色谱法测定
盐酸氟西汀分散片含量的高效液相色谱法测定
王素平;林丽珍
【期刊名称】《求医问药(学术版)》
【年(卷),期】2011(009)008
【摘要】目的:建立反相高效液相色谱法测定盐酸氟西汀分散片的含量.方法:采用
反相高效液相色谱法,色谱柱为C18,ψ (乙腈:四氢呋喃:三乙胺磷酸缓冲
液)=21:14:65为流动相,流速1.0ml/min,检测波长为226nm,测定盐酸氟西汀的含量.结果:盐酸氟西汀在36~84g/ml浓度范围内线性关系良好(r=0.9998),平均回收率为100.3%(RSD=1.0%,n=9),精密度(RSD)为0.6%(n=6).结论:本法简便、快速、准确、灵敏,重现性好,适用于盐酸氟西汀分散片的含量测定.
【总页数】3页(P235-235,237-238)
【作者】王素平;林丽珍
【作者单位】海南三叶制药厂有限公司,海南,海口,570226;海南三叶制药厂有限公司,海南,海口,570226
【正文语种】中文
【中图分类】R927.2
【相关文献】
1.高效液相色谱法测定盐酸氟西汀的含量 [J], 吴荷琴;陈朝霞
2.高效液相色谱法测定盐酸氟西汀胶囊含量 [J], 杨继红;宋琪雯;郑志昌;王培民;孙
为民;熊有贤;张力
3.HPLC法测定盐酸氟西汀分散片的含量 [J], 王素平;王昌锭;林丽珍
4.盐酸氟西汀分散片含量的高效液相色谱法测定 [J], 王素平;林丽珍
5.HPLC法测定盐酸氟西汀分散片的含量 [J], 王素平;王昌锭;林丽珍
因版权原因,仅展示原文概要,查看原文内容请购买。
制剂中某些微量吩噻嗪衍生物的直接滴定法
制剂中某些微量吩噻嗪衍生物的直接滴定法
陈珊
【期刊名称】《河北医科大学学报》
【年(卷),期】1983(000)001
【摘要】吩噻嗪衍生物用做为抗精神病,抗胆碱能和抗组织胺的药物。
有人报导过用阳极氧化和电流滴定以及极谱法测定微量吩噻嗪衍生物。
本文叙述一个用N-溴琥珀酰亚胺(NBS)简便快速测定微量吩噻嗪衍生物的方法。
实验 1.样品溶液:将样品25mg溶于蒸馏水中,转移至25ml容量瓶中并用水稀释到刻度。
2.0.02M N-溴琥珀酰亚胺溶液:精密称取0.3560g NBS,溶于少量的温蒸馏水中,用冷蒸馏水稀释至100ml,用碘量法标定。
3.操作步骤:取约含1-5mg药物溶液置于100ml滴定瓶中,加入2MHCl6ml和0.04%甲基红指示液2滴。
用0.02M NBS滴定至指示剂退色。
剩余的NBS用碘回滴。
然后,取等体积的NBS在同样条件下用
【总页数】1页(P43-43)
【作者】陈珊
【作者单位】
【正文语种】中文
【中图分类】R9
【相关文献】
1.N取代吩噻嗪衍生物的合成及其铜离子传感性能 [J], 张曼;马鹏;童碧海;张千峰
2.力致变色吩噻嗪衍生物的合成及其对2,4,6-三硝基苯酚的荧光检测 [J], 苏弘霖;
许炳佳;杨京莲;高敏;温钰旸;梁楸怡;郭化雷;张敏敏;区振杰;刘聪
3.药物制剂中吩噻嗪衍生物直接滴定法的微量测 [J], 周执中
4.吩噻嗪衍生物的合成及发光性能研究 [J], 周若楠
5.D-A型三苯胺-吩噻嗪衍生物的合成及其发光性能的研究 [J], 张文霞
因版权原因,仅展示原文概要,查看原文内容请购买。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :PyrimethamineCatalog No. :HY-18062CAS No. :58-14-01.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4),H302Acute aquatic toxicity (Category 1),H400Chronic aquatic toxicity (Category 1),H4102.2 GHS Label elements, including precautionary statementsPictogramSignal word WarningHazard statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effects.Precautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell.P330 Rinse mouth.P391 Collect spillage.P501 Dispose of contents/ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:Pirimecidan; Pirimetamin; RP 4753Formula:C12H13ClN4Molecular Weight:248.71CAS No. :58-14-04. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGUN number: 3077Class: 9Packing group: IIIEMS-No: F-A, S-FProper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.Marine pollutant: Marine pollutantIATAUN number: 3077Class: 9Packing group: IIIProper shipping name: Environmentally hazardous substance, solid, n.o.s.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。